Amy Duross Sells 2,000 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) Director Amy Duross sold 2,000 shares of BioLife Solutions stock in a transaction on Monday, December 15th. The shares were sold at an average price of $24.60, for a total value of $49,200.00. Following the transaction, the director owned 18,687 shares in the company, valued at $459,700.20. This represents a 9.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Amy Duross also recently made the following trade(s):

• On Tuesday, November 25th, Amy Duross sold 2,000 shares of BioLife Solutions stock. The stock was sold at an average price of $27.00, for a total value of $54,000.00.
• On Friday, November 21st, Amy Duross sold 1,000 shares of BioLife Solutions stock. The shares were sold at an average price of $26.00, for a total value of $26,000.00.
• On Thursday, November 20th, Amy Duross sold 4,523 shares of BioLife Solutions stock. The stock was sold at an average price of $24.51, for a total transaction of $110,858.73.
• On Wednesday, November 19th, Amy Duross sold 477 shares of BioLife Solutions stock. The stock was sold at an average price of $24.50, for a total transaction of $11,686.50.

BioLife Solutions Price Performance

BLFS traded up $0.40 on Wednesday, reaching $25.01. 296,709 shares of the company traded hands, compared to its average volume of 445,500. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -357.23 and a beta of 1.93. The stock’s 50 day moving average price is $26.39 and its 200-day moving average price is $24.51. BioLife Solutions, Inc. has a 52-week low of $19.10 and a 52-week high of $29.62.

Wall Street Analyst Weigh In

BLFS has been the subject of a number of recent research reports. Zacks Research downgraded BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a research note on Monday, November 24th. Finally, Wall Street Zen downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Sunday, November 30th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.75.

Hedge Funds Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming boosted its holdings in shares of BioLife Solutions by 353.1% during the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 1,490 shares during the period. Hantz Financial Services Inc. lifted its position in BioLife Solutions by 54.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock worth $48,000 after acquiring an additional 659 shares during the last quarter. US Bancorp DE lifted its position in BioLife Solutions by 243.7% during the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock worth $49,000 after acquiring an additional 1,528 shares during the last quarter. Quarry LP boosted its holdings in BioLife Solutions by 50.9% during the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after acquiring an additional 713 shares during the period. Finally, Ameritas Investment Partners Inc. grew its position in shares of BioLife Solutions by 12.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 441 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.